Similar to SYK inhibitors, BTK inhibitors are also being investigated in autoimmune diseases and some are approved for this purpose as for ITP, multiple sclerosis or graft-versus-host disease (GVHD) (226–228). This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.